NSE:ZEEL 5 December 2025

May 30, 2026, 9:55 AM EDT. Novo Nordisk (NYSE:NVO) reported revenue of $327.8 million and net income of $121.96 million, drawing investor attention. Despite a 13.13% gain in one month and 21.71% over three months, the 12-month total shareholder return fell 34.15%, signaling weakened long-term momentum. Shares trade at $45.58 against a narrative fair value of $95.00, indicating a potential undervaluation of 52%. The stock's valuation depends heavily on continued growth from its GLP-1 drug semaglutide, disciplined margins, and US pricing conditions. Risks include policy shifts and increased GLP-1 competition that could depress prices. Investors are advised to consider both potential upside and warning signs amid mixed short-term gains and long-term concerns.